论文部分内容阅读
目的:观察注射用甘氨双唑钠对宫颈癌术后根治性放疗后盆腔复发患者再程放疗的增敏效果、毒副反应和患者生存率。方法:收集2005-01-2009-04宫颈癌术后根治性放疗后局限于盆腔复发的患者共60例,按照病例-对照方法分为两组;两组患者均采用三维适形放疗,其中放疗过程中增敏组同期静脉滴入注射用甘氨双唑钠增敏(800 mg/m2),两组患者进行随访比较。结果:增敏组患者放疗第4、6周、放疗后3、12个月的肿瘤缓解率分别是56.7%、83.3%、90.0%和90.0%,与对照组相比差异有统计学意义,P<0.05;增敏组1年生存率为56.7%,均较对照组(26.7%)明显提高,两组相比差异有统计学意义;两组患者止痛效果均明显,毒副反应差异无统计学意义。结论:注射用甘氨双唑钠对宫颈癌术后放疗后盆腔复发放疗有较肯定的放射增敏作用。
OBJECTIVE: To observe the sensitization effect, toxicity and survival rate of glycopyrrolate sodium injection for reradiation in patients with pelvic recurrence after radical radiotherapy of cervical cancer. Methods: A total of 60 patients who were limited to pelvic recurrence after radical radiotherapy for cervical cancer from January 2005 to April 2009 were collected and divided into two groups according to the case-control method. Three-dimensional conformal radiotherapy was used in both groups, of which radiotherapy Sensitization during the same period of intravenous infusion of glycopyrrolate sodium injection sensitization (800 mg / m2), the two groups were followed up for comparison. Results: The response rates of tumors in sensitized group were 56.7%, 83.3%, 90.0% and 90.0% respectively at the 4th and 6th week after radiotherapy and at 3 and 12 months after radiotherapy. The difference was statistically significant compared with the control group, P <0.05; the one-year survival rate of sensitized group was 56.7%, which was significantly higher than that of control group (26.7%), the difference was statistically significant between the two groups; the analgesic effect was obvious in both groups, and there was no statistically significant difference significance. CONCLUSION: Sodium glycididazol for injection has certain radiosensitization effect on pelvic recurrence and radiotherapy after radiotherapy for cervical cancer.